Muhammad Shahzeb Khan1, Izza Shahid2, Stefan D Anker3, Scott D Solomon4, Orly Vardeny5, Erin D Michos6, Gregg C Fonarow7, Javed Butler8. 1. Department of Medicine, Cook County Health Sciences, Chicago, IL, USA. 2. Department of Medicine, Ziauddin Medical University, Karachi, Pakistan. 3. Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany. 4. Brigham and Women's Hospital, Heart & Vascular Center, Boston, MA, USA. 5. University of Minnesota, Minneapolis, MN, USA. 6. Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7. Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA, USA. 8. Department of Medicine, University of Mississippi Medical Center, 2500 N. State Street, Jackson, MS, 39216, USA. jbutler4@umc.edu.
Abstract
BACKGROUND: Due to the overlapping clinical features of coronavirus disease 2019 (COVID-19) and influenza, parallels are often drawn between the two diseases. Patients with pre-existing cardiovascular diseases (CVD) are at a higher risk for severe manifestations of both illnesses. Considering the high transmission rate of COVID-19 and with the seasonal influenza approaching in late 2020, the dual epidemics of COVID-19 and influenza pose serious cardiovascular implications. This review highlights the similarities and differences between influenza and COVID-19 and the potential risks associated with coincident pandemics. MAIN BODY: COVID-19 has a higher mortality compared to influenza with case fatality rate almost 15 times more than that of influenza. Additionally, a significantly increased risk of adverse outcomes has been noted in patients with CVD, with ~ 15 to 70% of COVID-19 related deaths having an underlying CVD. The critical care need have ranged from 5 to 79% of patients hospitalized due to COVID-19, a proportion substantially higher than with influenza. Similarly, the frequency of vascular thrombosis including deep venous thrombosis and pulmonary embolism is markedly higher in COVID-19 patients compared with influenza in which vascular complications are rarely seen. Unexpectedly, while peak influenza season is associated with increased cardiovascular hospitalizations, a decrease of ~ 50% in cardiovascular hospitalizations has been observed since the first diagnosed case of COVID-19, owing in part to deferred care. CONCLUSION: In the coming months, increasing efforts towards evaluating new interventions will be vital to curb COVID-19, especially as peak influenza season approaches. Currently, not enough data exist regarding co-infection of COVID-19 with influenza or how it would progress clinically, though it may cause a significant burden on an already struggling health care system. Until an effective COVID-19 vaccination is available, high coverage of influenza vaccination should be of utmost priority.
BACKGROUND: Due to the overlapping clinical features of coronavirus disease 2019 (COVID-19) and influenza, parallels are often drawn between the two diseases. Patients with pre-existing cardiovascular diseases (CVD) are at a higher risk for severe manifestations of both illnesses. Considering the high transmission rate of COVID-19 and with the seasonal influenza approaching in late 2020, the dual epidemics of COVID-19 and influenza pose serious cardiovascular implications. This review highlights the similarities and differences between influenza and COVID-19 and the potential risks associated with coincident pandemics. MAIN BODY: COVID-19 has a higher mortality compared to influenza with case fatality rate almost 15 times more than that of influenza. Additionally, a significantly increased risk of adverse outcomes has been noted in patients with CVD, with ~ 15 to 70% of COVID-19 related deaths having an underlying CVD. The critical care need have ranged from 5 to 79% of patients hospitalized due to COVID-19, a proportion substantially higher than with influenza. Similarly, the frequency of vascular thrombosis including deep venous thrombosis and pulmonary embolism is markedly higher in COVID-19patients compared with influenza in which vascular complications are rarely seen. Unexpectedly, while peak influenza season is associated with increased cardiovascular hospitalizations, a decrease of ~ 50% in cardiovascular hospitalizations has been observed since the first diagnosed case of COVID-19, owing in part to deferred care. CONCLUSION: In the coming months, increasing efforts towards evaluating new interventions will be vital to curb COVID-19, especially as peak influenza season approaches. Currently, not enough data exist regarding co-infection of COVID-19 with influenza or how it would progress clinically, though it may cause a significant burden on an already struggling health care system. Until an effective COVID-19 vaccination is available, high coverage of influenza vaccination should be of utmost priority.
Authors: Mohammad Madjid; Charles C Miller; Vladimir V Zarubaev; Ivan G Marinich; Oleg I Kiselev; Yury V Lobzin; Alexander E Filippov; Samuel Ward Casscells Journal: Eur Heart J Date: 2007-04-17 Impact factor: 29.983
Authors: Pablo Abuin; Alejandro Anderson; Antonio Ferramosca; Esteban A Hernandez-Vargas; Alejandro H Gonzalez Journal: Annu Rev Control Date: 2021-05-28 Impact factor: 6.091
Authors: Rhian M Touyz; Marcus O E Boyd; Tomasz Guzik; Sandosh Padmanabhan; Linsay McCallum; Christian Delles; Patrick B Mark; John R Petrie; Francisco Rios; Augusto C Montezano; Robert Sykes; Colin Berry Journal: CJC Open Date: 2021-06-16
Authors: Thomas M Drake; Aya M Riad; Cameron J Fairfield; Conor Egan; Stephen R Knight; Riinu Pius; Hayley E Hardwick; Lisa Norman; Catherine A Shaw; Kenneth A McLean; A A Roger Thompson; Antonia Ho; Olivia V Swann; Michael Sullivan; Felipe Soares; Karl A Holden; Laura Merson; Daniel Plotkin; Louise Sigfrid; Thushan I de Silva; Michelle Girvan; Clare Jackson; Clark D Russell; Jake Dunning; Tom Solomon; Gail Carson; Piero Olliaro; Jonathan S Nguyen-Van-Tam; Lance Turtle; Annemarie B Docherty; Peter Jm Openshaw; J Kenneth Baillie; Ewen M Harrison; Malcolm G Semple Journal: Lancet Date: 2021-07-17 Impact factor: 79.321